Cargando…

Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines

Psilocybin (1) is the major alkaloid found in psychedelic mushrooms and acts as a prodrug to psilocin (2, 4‐hydroxy‐N,N‐dimethyltryptamine), a potent psychedelic that exerts remarkable alteration of human consciousness. In contrast, the positional isomer bufotenin (7, 5‐hydroxy‐N,N‐dimethyltryptamin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenz, Claudius, Dörner, Sebastian, Trottmann, Felix, Hertweck, Christian, Sherwood, Alexander, Hoffmeister, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401598/
https://www.ncbi.nlm.nih.gov/pubmed/35483009
http://dx.doi.org/10.1002/cbic.202200183
_version_ 1784772998969950208
author Lenz, Claudius
Dörner, Sebastian
Trottmann, Felix
Hertweck, Christian
Sherwood, Alexander
Hoffmeister, Dirk
author_facet Lenz, Claudius
Dörner, Sebastian
Trottmann, Felix
Hertweck, Christian
Sherwood, Alexander
Hoffmeister, Dirk
author_sort Lenz, Claudius
collection PubMed
description Psilocybin (1) is the major alkaloid found in psychedelic mushrooms and acts as a prodrug to psilocin (2, 4‐hydroxy‐N,N‐dimethyltryptamine), a potent psychedelic that exerts remarkable alteration of human consciousness. In contrast, the positional isomer bufotenin (7, 5‐hydroxy‐N,N‐dimethyltryptamine) differs significantly in its reported pharmacology. A series of experiments was designed to explore chemical differences between 2 and 7 and specifically to test the hypothesis that the C‐4 hydroxy group of 2 significantly influences the observed physical and chemical properties through pseudo‐ring formation via an intramolecular hydrogen bond (IMHB). NMR spectroscopy, accompanied by quantum chemical calculations, was employed to compare hydrogen bond behavior in 4‐ and 5‐hydroxylated tryptamines. The results provide evidence for a pseudo‐ring in 2 and that sidechain/hydroxyl interactions in 4‐hydroxytryptamines influence their oxidation kinetics. We conclude that the propensity to form IMHBs leads to a higher number of uncharged species that easily cross the blood‐brain barrier, compared to 7 and other 5‐hydroxytryptamines, which cannot form IMHBs. Our work helps understand a fundamental aspect of the pharmacology of 2 and should support efforts to introduce it (via the prodrug 1) as an urgently needed therapeutic against major depressive disorder.
format Online
Article
Text
id pubmed-9401598
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-94015982022-08-26 Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines Lenz, Claudius Dörner, Sebastian Trottmann, Felix Hertweck, Christian Sherwood, Alexander Hoffmeister, Dirk Chembiochem Research Articles Psilocybin (1) is the major alkaloid found in psychedelic mushrooms and acts as a prodrug to psilocin (2, 4‐hydroxy‐N,N‐dimethyltryptamine), a potent psychedelic that exerts remarkable alteration of human consciousness. In contrast, the positional isomer bufotenin (7, 5‐hydroxy‐N,N‐dimethyltryptamine) differs significantly in its reported pharmacology. A series of experiments was designed to explore chemical differences between 2 and 7 and specifically to test the hypothesis that the C‐4 hydroxy group of 2 significantly influences the observed physical and chemical properties through pseudo‐ring formation via an intramolecular hydrogen bond (IMHB). NMR spectroscopy, accompanied by quantum chemical calculations, was employed to compare hydrogen bond behavior in 4‐ and 5‐hydroxylated tryptamines. The results provide evidence for a pseudo‐ring in 2 and that sidechain/hydroxyl interactions in 4‐hydroxytryptamines influence their oxidation kinetics. We conclude that the propensity to form IMHBs leads to a higher number of uncharged species that easily cross the blood‐brain barrier, compared to 7 and other 5‐hydroxytryptamines, which cannot form IMHBs. Our work helps understand a fundamental aspect of the pharmacology of 2 and should support efforts to introduce it (via the prodrug 1) as an urgently needed therapeutic against major depressive disorder. John Wiley and Sons Inc. 2022-05-18 2022-07-05 /pmc/articles/PMC9401598/ /pubmed/35483009 http://dx.doi.org/10.1002/cbic.202200183 Text en © 2022 The Authors. ChemBioChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Lenz, Claudius
Dörner, Sebastian
Trottmann, Felix
Hertweck, Christian
Sherwood, Alexander
Hoffmeister, Dirk
Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines
title Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines
title_full Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines
title_fullStr Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines
title_full_unstemmed Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines
title_short Assessment of Bioactivity‐Modulating Pseudo‐Ring Formation in Psilocin and Related Tryptamines
title_sort assessment of bioactivity‐modulating pseudo‐ring formation in psilocin and related tryptamines
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401598/
https://www.ncbi.nlm.nih.gov/pubmed/35483009
http://dx.doi.org/10.1002/cbic.202200183
work_keys_str_mv AT lenzclaudius assessmentofbioactivitymodulatingpseudoringformationinpsilocinandrelatedtryptamines
AT dornersebastian assessmentofbioactivitymodulatingpseudoringformationinpsilocinandrelatedtryptamines
AT trottmannfelix assessmentofbioactivitymodulatingpseudoringformationinpsilocinandrelatedtryptamines
AT hertweckchristian assessmentofbioactivitymodulatingpseudoringformationinpsilocinandrelatedtryptamines
AT sherwoodalexander assessmentofbioactivitymodulatingpseudoringformationinpsilocinandrelatedtryptamines
AT hoffmeisterdirk assessmentofbioactivitymodulatingpseudoringformationinpsilocinandrelatedtryptamines